Vanguard Group
RLAY icon

Vanguard Group’s Relay Therapeutics RLAY Stock Holding History

Vanguard Group’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$82M Buy
9,691,445
+295,701
+3% +$2.11M ﹤0.01% 1947
2025
Q3 		$49M Buy
9,395,744
+15,893
+0.2% +$60.6K ﹤0.01% 2163
2025
Q2 		$32.5M Sell
9,379,851
-2,725,569
-23% -$8.11M ﹤0.01% 2325
2025
Q1 		$31.7M Sell
12,105,420
-2,924,789
-19% -$11.5M ﹤0.01% 2289
2024
Q4 		$61.9M Buy
15,030,209
+566,595
+4% +$3.08M ﹤0.01% 2075
2024
Q3 		$102M Buy
14,463,614
+2,758,748
+24% +$20.6M ﹤0.01% 1860
2024
Q2 		$76.3M Sell
11,704,866
-110,803
-0.9% -$757K ﹤0.01% 1964
2024
Q1 		$98.1M Buy
11,815,669
+1,165,282
+11% +$11.4M ﹤0.01% 1878
2023
Q4 		$117M Buy
10,650,387
+98,025
+0.9% +$827K ﹤0.01% 1781
2023
Q3 		$88.7M Buy
10,552,362
+23,795
+0.2% +$256K ﹤0.01% 1872
2023
Q2 		$132M Buy
10,528,567
+29,053
+0.3% +$361K ﹤0.01% 1694
2023
Q1 		$173M Buy
10,499,514
+115,296
+1% +$2.07M ﹤0.01% 1527
2022
Q4 		$155M Buy
10,384,218
+2,024,698
+24% +$38.8M ﹤0.01% 1575
2022
Q3 		$187M Buy
8,359,520
+1,261,066
+18% +$27.7M 0.01% 1424
2022
Q2 		$119M Buy
7,098,454
+880,831
+14% +$18.9M ﹤0.01% 1714
2022
Q1 		$186M Buy
6,217,623
+19,181
+0.3% +$465K ﹤0.01% 1601
2021
Q4 		$190M Buy
6,198,442
+1,314,405
+27% +$41.5M ﹤0.01% 1642
2021
Q3 		$154M Buy
4,884,037
+590,595
+14% +$19.9M ﹤0.01% 1749
2021
Q2 		$157M Buy
4,293,442
+242,361
+6% +$7.99M ﹤0.01% 1758
2021
Q1 		$140M Buy
4,051,081
+2,330,406
+135% +$101M ﹤0.01% 1772
2020
Q4 		$71.5M Buy
1,720,675
+88,701
+5% +$4.01M ﹤0.01% 2016
2020
Q3 		$69.5M Buy
+1,631,974
New +$62.2M ﹤0.01% 1852

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Group's RLAY Position: Q4 2025 in Review

Vanguard Group increased its Relay Therapeutics (RLAY) stake by 3.1% in Q4 2025, buying an estimated $2.11M and bringing the position to 9,691,445 shares worth $82M. The position accounts for ﹤0.01% of the portfolio, ranked #1947.

Vanguard Group first reported a position in RLAY in Q3 2020 and has held it in 22 quarters since. The position peaked at $190M in Q4 2021. 227 funds tracked by Wall St. Rank hold RLAY as of Q4 2025.

  • Vanguard Group held 9,691,445 shares of Relay Therapeutics worth $82M as of Q4 2025.
  • Vanguard Group bought 295,701 Relay Therapeutics shares in Q4 2025, an estimated $2.11M.
  • Relay Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1947 holding.
  • Vanguard Group first reported a position in Relay Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • Vanguard Group's Relay Therapeutics position peaked at $190M in Q4 2021.
  • 227 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.